Colchicine cuts events in patients with coronary disease: landmark trial
The result could change practice, researchers say, despite a niggling concern over non-cardiovascular deaths
Low-dose colchicine could cut the risk of cardiovascular death or further events by almost one third in patients with chronic coronary disease, a landmark Australian-led study shows.
The findings, presented at the European Society of Cardiology virtual congress on Tuesday, could lead to the gout medication being incorporated into clinical guidelines, the researchers say.
